文献速递泌尿生殖技术与安全CT

N-乙酰半胱氨酸预防静脉对比剂后急性肾损伤的系统评价与荟萃分析

Efficacy and safety of N-acetylcysteine for preventing post-intravenous contrast acute kidney injury in patients with kidney impairment: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2023-04-18

该系统评价纳入截至2022年5月的随机对照试验,评估N-乙酰半胱氨酸(NAC)预防肾功能不全患者接受静脉对比剂后急性肾损伤(PC-AKI)的疗效与安全性。结果显示NAC未显著降低PC-AKI风险(RR 0.47,95%CI 0.20-1.11)、全因死亡率或住院时间,证据确定性低至极低。

要点

  • 对于肾功能不全患者,静脉对比剂前预防性使用NAC可能不显著降低PC-AKI风险。
  • NAC对全因死亡率和住院时间的影响不显著,证据确定性极低。
  • 该结论基于低确定性证据,临床决策需结合个体情况。

诊断标准与关键数值

  • PC-AKI风险:RR 0.47(95%CI 0.20-1.11;8项研究;545例受试者;I²=56%;低确定性)。
  • 全因死亡率:RR 0.67(95%CI 0.29-1.54;2项研究;129例受试者;极低确定性)。
  • 住院时间:均数差9.2天(95%CI -20.08至38.48;1项研究;42例受试者;极低确定性)。

局限性

  • 纳入研究数量少、样本量小,证据确定性低至极低。
  • 对肾脏替代治疗需求和严重不良事件等结局无法确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: N-Acetylcysteine (NAC) may confer protection against post-contrast acute kidney injury (PC-AKI), although evidence is sparse and conflicting. The objective was to analyse the evidence on the efficacy and safety of NAC vs no administration of NAC in preventing PC-AKI in patients with pre-existing kidney impairment undergoing a non-interventional radiological examination requiring intravenous (IV) contrast media (CM) administration.

METHODS: We carried out a systematic review including randomised controlled trials (RCTs) published in MEDLINE, EMBASE, and Clinicaltrials.gov up to May 2022. The primary outcome was PC-AKI. Secondary outcomes included the requirement of renal replacement therapy, all-cause mortality, serious adverse events, and length of hospital stay. We conducted the meta-analyses using the Mantel-Haenszel method and following a random-effects model.

RESULTS: NAC was not associated with a significant reduction in PC-AKI (RR 0.47, 95%CI 0.20 to 1.11; 8 studies; 545 participants; I2: 56%; low certainty), all-cause mortality (RR 0.67, 95%CI 0.29 to 1.54; 2 studies; 129 participants; very low certainty), or length of hospital stay (mean difference 9.2 days, 95%CI - 20.08 to 38.48; 1 study; 42 participants; very low certainty). The impact on other outcomes could not be determined.

CONCLUSIONS: NAC may not reduce the risk of PC-AKI or all-cause mortality in people with kidney impairment who receive an IV CM prior to radiological imaging, although the certainty of the evidence is very low or low.

CLINICAL RELEVANCE STATEMENT: Our review concludes that prophylactic administration of N-acetylcysteine may not significantly reduce the risk of acute kidney injury in patients with kidney impairment receiving an intravenous contrast media prior to non-interventional radiological imaging, which may support decision making in this common clinical scenario.

KEY POINTS: • N-Acetylcysteine may not significantly reduce the risk of acute kidney injury in patients with kidney impairment receiving an intravenous contrast media prior to non-interventional radiological imaging. • All-cause mortality and length of hospital stay would not be decreased with the administration of N-Acetylcysteine in this setting.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Maestro, Leache, Gutiérrez-Valencia, et al. Efficacy and safety of N-acetylcysteine for preventing post-intravenous contrast acute kidney injury in patients with kidney impairment: a systematic review and meta-analysis. Eur Radiol. 2023. PMID: 37071164. doi:10.1007/s00330-023-09577-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。